Evidence map›Paper›PMID 37201027›Full record

ArticleFrontiers in pharmacology2023

A novel risk model of three SUMOylation genes based on RNA expression for potential prognosis and treatment sensitivity prediction in kidney cancer.

Song-Chao Li, Li-Jie Yan, Xu-Liang Wei, Zhan-Kui Jia, Jin-Jian Yang, Xiang-Hui Ning

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Song-Chao LiDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Li-Jie YanInstitute of Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Xu-Liang WeiInstitute of Pharmaceutical Science, Zhengzhou University, Zhengzhou, China.
Zhan-Kui JiaDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jin-Jian YangDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiang-Hui NingDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

ANATOMY OF THE AUDITORY SYSTEMR01DC000127 · NIDCD · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MOREST, DONALD KENT · 1989 to 2010
$2.5M
NIDCD NIH HHS R01 DC000127
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune threapykidney cancerprognosissumoylationtargeted therapy

Identifiers

PMID37201027
PMCPMC10185777
OpenAlexW4367679055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.